Blinatumomab Assigned Breakthrough Therapy Designation to Treat Acute Lymphoblastic Leukemia
the Cancer Therapy Advisor take:
Amgen has announced that the U.S. Food and Drug Administration (FDA) has designated its drug, blinatumomab, breakthrough therapy status. Blinatumomab is an investigational bispecific T-cell engager (BiTE) antibody currently being studied for the treatment of adults with Philadelphia chromosome-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).
The FDA granted this status based on the results of Amgen's phase 2 trial presented at the American Society of Clinical Oncology (ASCO) annual meeting. In the study, 189 adults with Ph-negative relapsed/refractory B-precursor ALL were treated with blinatumomab.
Of those, 43% experienced a complete response and relapse-free survival duration was 5.9 months. Overall survival duration was 6.1 months. The most common grade 3 adverse events observed were febrile neutropenia, neutropenia, and anemia.
A phase 3 study testing blinatumomab in patients with Ph- ALL is currently underway. According to the American Cancer Society, about 6,000 adults will be diagnosed with ALL in 2014, and nearly 1,500 will die from the disease.
Amgen has announced that the FDA has designated its drug, blinatumomab, Breakthrough Therapy status.
The FDA states that Breakthrough Therapy Designation is intended to expedite the development and review of drugs for serious or life-threatening conditions.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Immune Signature for Renal Cell Papillary Carcinoma Predicts Outcome
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed